Skip to main navigation Skip to main content
The University of Southampton
News

Lung Cancer Awareness Month - The TOURIST Trial Platform Q&A

Published: 2025-11-25 20:30:00

November is Lung Cancer Awareness Month.

To mark the month, we are highlighting the TOURIST trial platform, the world’s largest clinical trial using radiotherapy in the treatment of metastatic lung cancer.

Lung cancer is the 3rd most common cancer in the UK*, but is the biggest cancer killer, accounting for 21% of cancer deaths annually.

Between 85 and 90 per cent of cases diagnosed are a type of cancer called Non-Small Cell Lung Cancer (NSCLC). Nearly half of these cancers are diagnosed at a late stage when the disease has spread and is incurable, meaning treatment focuses on controlling symptoms and extending life, rather than curing.

The TOURIST platform has been set up to see if radiotherapy, alongside other treatments, improves outcomes and quality of life. There are currently 2 studies in the platform which are recruiting patients – PRINCE and QUARTZ Lung.

Jacqui Gath is a public partner on the TOURIST trial team, helping feedback on the research from the patient perspective.

For Lung Cancer Awareness Month, Jacqui spoke to the Chief Investigators of the platform to ask the questions that patients might have about taking part.

The TOURIST Trial Platform

Jacqui speaks to Dr David Woolf, consultant oncologist at The Christie and joint chief investigator for TOURIST, about what the trial platform is, and the two trials currently running in the platform.

The TOURIST PRINCE trial

Jacqui speaks to Professor Matthew Hatton, honorary professor of oncology at The University of Sheffield and Chief Investigator for the TOURIST PRINCE trial about what the trial is aiming to find out and who can take part.

The TOURIST QUARTZ LUNG Trial

Jacqui speaks again to Dr David Woolf about the second trial in the TOURIST platform, QUARTZ LUNG, looking at radiotherapy for patients who have finished, or cannot have, drug treatment.

The TOURIST trial is sponsored by The Christie NHS Foundation Trust in Manchester and managed by Southampton Clinical Trials Unit.

The research is made possible thanks to a £3.4m grant from the National Institute for Health and Care Research (NIHR).

*Figures from Cancer Research UK .

Privacy Settings